Literature DB >> 17335951

Serotonin transporter density and anxiolytic-like effects of antidepressants in mice.

N R Mirza1, E Ø Nielsen, K B Troelsen.   

Abstract

BACKGROUND: Chronic treatment with the dual serotonin/noradrenaline reuptake inhibitor (SNRI) duloxetine reduces the density of serotonin transporter sites in cortex and engenders an anxiolytic-like response. To determine the reproducibility of these effects and their generality to other antidepressants we compared the effects of chronic duloxetine treatment with another SNRI, venlafaxine, and two selective serotonin reuptake inhibitors, paroxetine and fluoxetine.
METHODS: Separate groups of mice were administered vehicle, fluoxetine (15 mg/kg), paroxetine, duloxetine or venlafaxine (10 mg/kg) perorally twice daily for 28 days and tested in the mouse zero-maze and in motility cages on days 21 and 22, respectively, to determine effects on anxiety and motor activity. On day 28 brains were analysed for serotonin transporter (SERT) density in cortex and noradrenaline transporter (NET) density in cortex and hippocampus.
RESULTS: Duloxetine and fluoxetine both reduced SERT density in cortex and induced anxiolytic-like effects. Paroxetine had an identical profile, but it is unclear if this drug down-regulated the SERT since extensive washing of cortical tissue did not remove all drug. Venlafaxine had no effect on behavioural or biochemical parameters. Only duloxetine reduced NET density in cortex, although not hippocampus.
CONCLUSIONS: The reduction in SERT density and anxiolytic-like effects with duloxetine, fluoxetine and, potentially, paroxetine suggest that down-regulation of the SERT may be a relevant mechanism in therapeutic response to these antidepressants.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17335951     DOI: 10.1016/j.pnpbp.2007.01.020

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  23 in total

Review 1.  Pharmacogenetics of antidepressant response.

Authors:  Stefano Porcelli; Antonio Drago; Chiara Fabbri; Sara Gibiino; Raffaella Calati; Alessandro Serretti
Journal:  J Psychiatry Neurosci       Date:  2011-03       Impact factor: 6.186

2.  Synthesis, radiosynthesis, and biological evaluation of fluorine-18-labeled 2beta-carbo(fluoroalkoxy)-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes: candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography.

Authors:  Jeffrey S Stehouwer; Nachwa Jarkas; Fanxing Zeng; Ronald J Voll; Larry Williams; Vernon M Camp; Eugene J Malveaux; John R Votaw; Leonard Howell; Michael J Owens; Mark M Goodman
Journal:  J Med Chem       Date:  2008-12-25       Impact factor: 7.446

Review 3.  The genetics of obsessive-compulsive disorder and Tourette's syndrome: what are the common factors?

Authors:  Marco A Grados
Journal:  Curr Psychiatry Rep       Date:  2009-04       Impact factor: 5.285

Review 4.  Antidepressant Withdrawal and Rebound Phenomena.

Authors:  Jonathan Henssler; Andreas Heinz; Lasse Brandt; Tom Bschor
Journal:  Dtsch Arztebl Int       Date:  2019-05-17       Impact factor: 5.594

Review 5.  Ontogeny and regulation of the serotonin transporter: providing insights into human disorders.

Authors:  Lynette C Daws; Georgianna G Gould
Journal:  Pharmacol Ther       Date:  2011-04-05       Impact factor: 12.310

6.  Fluorine-18 Radiolabeled PET Tracers for Imaging Monoamine Transporters: Dopamine, Serotonin, and Norepinephrine.

Authors:  Jeffrey S Stehouwer; Mark M Goodman
Journal:  PET Clin       Date:  2009-01

7.  The role of duloxetine in the treatment of anxiety disorders.

Authors:  Domenico De Berardis; Nicola Serroni; Alessandro Carano; Marco Scali; Alessandro Valchera; Daniela Campanella; Alessandro D'Albenzio; Berardo Di Giuseppe; Francesco Saverio Moschetta; Rosa Maria Salerno; Filippo Maria Ferro
Journal:  Neuropsychiatr Dis Treat       Date:  2008-10       Impact factor: 2.570

8.  Serotonin synthesis, release and reuptake in terminals: a mathematical model.

Authors:  Janet Best; H Frederik Nijhout; Michael Reed
Journal:  Theor Biol Med Model       Date:  2010-08-19       Impact factor: 2.432

9.  Profiling of behavioral changes and hippocampal gene expression in mice chronically treated with the SSRI paroxetine.

Authors:  Inge Sillaber; Markus Panhuysen; Markus S H Henniger; Frauke Ohl; Claudia Kühne; Benno Pütz; Thomas Pohl; Jan M Deussing; Marcelo Paez-Pereda; Florian Holsboer
Journal:  Psychopharmacology (Berl)       Date:  2008-07-16       Impact factor: 4.530

10.  Chronic oral nicotine increases brain [3H]epibatidine binding and responsiveness to antidepressant drugs, but not nicotine, in the mouse forced swim test.

Authors:  Jesper T Andreasen; Elsebet O Nielsen; John P Redrobe
Journal:  Psychopharmacology (Berl)       Date:  2009-05-12       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.